Abstract
Resistance to BRAF/MEK inhibitor treatment occurs in most patients with advanced BRAFV600-mutant melanoma. Intermittent drug dosing had been proposed as a strategy to circumvent resistance. In a clinical trial published in Nature Medicine, continuous dosing of BRAF/MEK inhibitors produced superior progression-free survival compared to intermittent dosing in BRAFV600-mutant melanoma patients.
Original language | English |
---|---|
Pages (from-to) | 779-781 |
Number of pages | 3 |
Journal | Cancer Cell |
Volume | 38 |
Issue number | 6 |
DOIs | |
Publication status | Published - 14 Dec 2020 |